Alpha 2.0
Login Register
» Articles » PMID: 4402420

Acetylator Phenotype and Adverse Effects of Sulphasalazine in Healthy Subjects

Overview
Journal Gut
Specialty Gastroenterology
Date 1972 Apr 1
PMID 4402420
Citations 32
Authors
H Schroder
D A Evans
Affiliations
Soon will be listed here.
Abstract

Sulphasalazine (salicyl-azo-sulphapyridine) was ingested by 27 healthy subjects for five days at a dosage of 4 g daily. The acetylator phenotype of each subject had been established previously. The serum concentrations of the parent drug and its sulphapyridine-metabolites were determined and the adverse effects were recorded. There was no correlation between the serum concentrations of sulphasalazine and the adverse effects. The slow acetylators obtained enhancement of serum concentrations of sulphapyridine earlier than the rapid acetylators. They also reported adverse effects earlier and of more pronounced nature than the rapid acetylators. The data as a whole suggest that the adverse effects observed were caused by the metabolite sulphapyridine and that they are influenced by the polymorphic acetylation.

Citing Articles

The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis.

Yee J, Kim S, Han J, Lee N, Yoon H, Gwak H Sci Rep. 2020; 10(1):3658.

PMID: 32107440 PMC: 7046788. DOI: 10.1038/s41598-020-60467-8.

Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.

Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng A Cochrane Database Syst Rev. 2019; 6:CD008414.

PMID: 31220875 PMC: 6586553. DOI: 10.1002/14651858.CD008414.pub3.

Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease.

Akobeng A, Zhang D, Gordon M, MacDonald J Cochrane Database Syst Rev. 2016; 9:CD003715.

PMID: 27681657 PMC: 6457838. DOI: 10.1002/14651858.CD003715.pub3.

Medical management of ulcerative colitis with a specific focus on 5-aminosalicylates.

Freeman H Clin Med Insights Gastroenterol. 2014; 5:77-83.

PMID: 24833937 PMC: 3987765. DOI: 10.4137/CGast.S8673.

The etiology and management of leukopenia.

Ing V Can Fam Physician. 2011; 30:1835-9.

PMID: 21279100 PMC: 2154209.

References
1.
Collins J . Adverse reactions to salicylazosulfapyridine (azulfidine) in the treatment of ulcerative colitis. South Med J. 1968; 61(4):354-8. DOI: 10.1097/00007611-196804000-00005. View
2.
Evans D . An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969; 6(4):405-7. PMC: 1468783. DOI: 10.1136/jmg.6.4.405. View
3.
MORRISON L . Results of treatment of ulcerative colitis with salicylazosulfapyridine. Gastroenterology. 1952; 21(1):133-8. View
4.
DEVADATTA S, GANGADHARAM P, Andrews R, Fox W, Ramakrishnan C, Selkon J . Peripheral neuritis due to isoniazid. Bull World Health Organ. 1960; 23:587-98. PMC: 2555613. View
5.
Watkinson G . Medical management of ulcerative colitis. Br Med J. 1961; 1(5220):147-51. PMC: 1952956. DOI: 10.1136/bmj.1.5220.147. View